INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
10/05/2026
Voltar para busca
Dado oficial do USPTO
A
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
50
Atualização mais recente
11/05/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 9, 42
Data de depósito
16/10/2013
Data de registro
14/10/2014
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/09/2025
Última transação
11/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
Schindellegi, CH
Examinador
LAVACHE, LINDA M
Localização atual
Historical data usage
Descrição da marca
The mark consists of the letter "A" formed by three oblong shapes.
Titulares e representantes
Titulares
AsedaSciences AG
AsedaSciences AG
AsedaSciences GmbH
Representantes
Jeffery A. Smith MILLEN WHITE ZELANO & BRANIGAN, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
In vitro diagnostic preparations for medical use; diagnostic test reagents for medical use; chemical reagents for medical or veterinary use; diagnostic reagents and contrast media agents for medical use; Medical diagnostic reagents; Reagents for medical use
Classe 9
Measuring apparatus and instrumentsfree flow electrophoresis equipment for protein separation and isolationflow cytometry analyzers for cellular analysis; scientificopticalmeasuringsignaling and checking apparatus and instrumentsfree flow electrophoresis equipment for protein separation and isolationflow cytometers for single cell and population based cellular analysis; measuring and testing machines and instrumentsprotein separation and isolation instrumentsflow cytometerslaboratory liquid handlers and automation for testing and implementing cellular based screening methods; laboratory apparatus and instruments for use in growingmaintainingevaluating and quality control of cell culturesautomated liquid dispensingprotein separation and isolationsingle cell and population based cellular analysisthe assessment of compound or drug effects on cellular physiology and biologynot for medical purposes; chemistry apparatus and instruments for maintainingevaluating and quality control of cell culturesautomated liquid dispensing of compound preparations and chemical reagentsprotein separation and isolationsingle cell and population based cellular analysisthe assessment of compound or drug effects on cellular physiology and biologynot for medical purpose
Classe 42
Scientific research and development; scientific and technological servicesnovel multi-parametric phenotypic screening in the nature of analytical testing services and protein isolation for the characterization and simultaneous identification of multiple biological and physiological effects caused by drug candidates on live human cell models in the field of pharmaceutical researchdrug discovery and characterization of compound effectscientific research and development relating thereto; Scientific and technological services for scientific analysistesting and research in the fields of pharmaceutical researchdrug discovery and characterization of compound effectprotein separationisolation and characterization; scientific research services; scientific testing and analysis in the fields of pharmaceutical researchdrug discovery and characterization of compound effectprotein separationisolation and characterization; computer-assisted scientific researchtesting and analysis services in the fields of pharmaceutical researchdrug discovery and characterization of compound effect by using mathematical and statistical algorithms to compare and predict the effect of a target compound to that of an approved drug or known toxinwhere a biological fingerprint is created and analyzed by measuring the broad physiological and biological effect of said compounds on live human cells; laboratory research and analysis services in the fields of pharmaceutical researchdrug discovery and characterization of chemical compoundsprotein separationisolation and characterization; pharmaceutical research and development; Scientific research and scientific and technological servicesanalytical testing and phenotypic screening services in the fields of pharmaceutical researchdrug discovery and characterization of chemical compoundsprotein separationisolation and characterization; scientific laboratory services in the fields of pharmaceutical researchdrug discovery and characterization of chemical compoundsprotein separationisolation and characterization; scientific and technological servicesanalytical testing and phenotypic screening services in the fields of pharmaceutical researchdrug discovery and characterization of chemical compoundsprotein separationisolation and characterization; provision of information about medical and scientific research in the field of pharmaceuticals; preparation of reports on scientific research ; provision of scientific information on technological research in the fields of pharmaceutical researchdrug discovery and characterization of chemical compounds; provision of scientific information about industrial analysis and research services in the fields of pharmaceutical researchdrug discovery and characterization of chemical compounds; provision of information and data relating to medical research and development and veterinary medical research; consultancy services in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; engineering and scientific consultancy services in the fields of pharmaceutical researchdrug discovery and characterization of chemical compoundsprotein separationisolation and characterization; provision of technical advice in the field of scientific and industrial research; consultancy in the field of scientific and industrial research
Publicações
Histórico de despachos e eventos da marca no USPTO.
50 publicações encontradas
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
09/09/2025
71AG
REGISTERED-SEC.71 ACCEPTED
09/09/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
13/08/2025
PC.D
PETITION TO DIRECTOR DISMISSED
11/08/2025
APET
ASSIGNED TO PETITION STAFF
11/08/2025
TPDR
TEAS PETITION TO DIRECTOR RECEIVED
14/04/2025
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
14/10/2023
RNWL
INTERNATIONAL REGISTRATION RENEWED
29/09/2023
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
07/06/2023
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
27/03/2023
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
20/09/2022
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
03/08/2022
INPC
INVALIDATION PROCESSED
03/08/2022
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
30/04/2022
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
30/08/2021
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
30/08/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
27/08/2021
ES75
TEAS SECTION 71 & 15 RECEIVED
14/04/2021
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
14/10/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
24/04/2015
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/03/2015
FIMP
FINAL DISPOSITION PROCESSED
11/03/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
14/01/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
14/10/2014
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
31/07/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/07/2014
PUBO
PUBLISHED FOR OPPOSITION
29/07/2014
GPNX
NOTIFICATION PROCESSED BY IB
24/07/2014
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/07/2014
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/07/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/07/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
26/06/2014
ALIE
ASSIGNED TO LIE
25/06/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/06/2014
XAEC
EXAMINER'S AMENDMENT ENTERED
09/06/2014
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/06/2014
GNEA
EXAMINERS AMENDMENT E-MAILED
09/06/2014
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/06/2014
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/03/2014
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/03/2014
RFNT
REFUSAL PROCESSED BY IB
22/02/2014
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/02/2014
RFRR
REFUSAL PROCESSED BY MPU
06/02/2014
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/02/2014
CNRT
NON-FINAL ACTION WRITTEN
05/02/2014
DOCK
ASSIGNED TO EXAMINER
31/01/2014
MAFR
APPLICATION FILING RECEIPT MAILED
17/12/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/12/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/12/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace A ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.